British Journal of Haematology

Article	Citations
e‐Posters	125
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 2021	122
Don't forget cord blood in non‐remission acute myeloid leukaemia!	91
Issue Information	86
Issue Information	84
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia	81
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	79
How to dose and monitor argatroban for treatment of HIT	71
	63
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	60
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	60
Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma	57
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	54
Immunophenotypic clustering in paediatric acute myeloid leukaemia	54
Issue Information	53
A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia	50
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	50
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	49
Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia	49
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	48
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data	47
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)	45
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	42
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression	42
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	41

The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	39
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients	39
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry	38
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	38
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	38
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation	36
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	36
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study	35
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	35
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.	34
Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle	34
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	32
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	32
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	31
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	31
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells	31
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	30
The role of genetics in refractory immune thrombocytopenia	29
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	29
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	29
The oldest case of lymphoma? Insights from a XIII century fresco	29
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	29
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond	28
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	28
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	28
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation	28
Would you like to take some more ruxolitinib after your fedratinib?	28
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	27
	27
Indirect presentation of mismatched human leukocyte antigen‐B associates with outcomes of cord blood transplantation	27
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi‐structured interviews	26
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	26
Empagliflozin modulates CD4+ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia	26
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	25
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	25
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	25
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	25
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complet	25
Prolonged platelet hyperactivity after COVID‐19 infection	25
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	24
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	24
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium	24
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	24
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline	24
Immune thrombocytopenia (ITP) in pregnancy	23
Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers	23
Screening for monoclonal gammopathy of undetermined significance is contraindicated	23
Obituary Dr Christine Costello: MBChB, DRCOG, FRCP, FRCPath 29 August 1945–31 December 2021	23
Issue Information	23
Are HPA‐5b antibodies a significant cause of FNAIT and associated bleeding or merely an incidental finding?	23

Issue Information	23
Issue Information	22
Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring	22
	22
	21
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model	21
Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma	21
Successful combined anti‐CD19 immunotherapy of relapsed acute lymphoblastic leukaemia in a child with Nijmegen breakage syndrome	21
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease	21
Bridging the implementation gap in medication adherence. If you build it, will they come?	20
Association of human leucocyte antigen loci with vaccine‐induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4‐derived peptides and MHC‐	20
Erratum to: The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia	20
The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia	20
A synonymous variant is unmasked in thalassaemia	20
Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment	20
Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma	20
Facing the bleeding risk of caplacizumab in postpartum immune thrombotic thrombocytopenic purpura in constrained resource settings	20
Another side of IgA neoplastic plasma cells	20
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study	20
A defined serum‐free culture system for human long‐term haematopoietic stem cells	20
A single dose of eculizumab terminated life‐threatening haemolysis in idiopathic IgM‐mediated warm autoimmune haemolytic anaemia: A case report	20
Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia	20
Correction to “Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib”LiM, LiuL, DingB, SongX, XiaA, HanY, et al. Refractory/relapse thrombocytope	20
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report	20
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis	20
Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup	20
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia	19
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia	19
Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state	19
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia	19
Clinical decision support to reduce unnecessary diagnostic testing for heparin‐induced thrombocytopenia	19
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia	19
Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real‐world clinical practices	19
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia	19
Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T‐ALL	19
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma—Response	19
Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients	19
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia	18
Concurrence of mixed cryoglobulinaemia and cold agglutinin disease, and the putative role for a stereotyped immunoglobulin light chain	18
Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis	18
Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease	18
Novel transferrin gene mutations in four new cases of congenital Atransferrinaemia: Functional and diagnostic pathogenicity despite negative bioinformatics	18
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant	18
The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman‐like lymphadenopathies: A 20‐year retrospective analysis of clinical and pathological features	18
Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis	18
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post‐transplant clinical outcome in patients with aggressive ATL	18
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome	18
Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone marrow	18
Assessment of neurocognitive functioning in sickle cell disease and thalassaemia and the association with silent cerebral infarcts, cerebral haemodynamics and oxygen metabolism	18
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy	18
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis	18
Factor VII deficiency: A cause of (or risk factor for) bleeding?	18
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease	18
Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload	18
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study	17
Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma	17
Iron parameters in pregnant women with beta‐thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supple	17
Issue Information	17
Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm	17
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	17
Correction to ‘Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10AML with extensive extramedullary infiltration: A	17
Management of cardiovascular complications of bruton tyrosine kinase inhibitors	17
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	17
A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies	17
Antibody response and intra‐host viral evolution after plasma therapy in COVID‐19 patients pre‐exposed or not to B‐cell‐depleting agents	17
	17
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy	16
Issue Information	16
Erratum	16
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study	16
Dysplastic plasma cells in multiple myeloma	16
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis	16
	16
t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia	16
Issue Information	16
Issue Information	16
	16
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis	16
Issue Information	16
Up‐regulation of miR‐130a is related to leg ulcers in sickle cell anaemia	16

Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells	16
	16
The impact of B‐cell‐directed therapy on SARS‐CoV‐2 vaccine efficacy in chronic lymphocytic leukaemia	16
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies	16
Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies	16
The usefulness of indium‐111 platelet scintigraphy beyond predicting efficacy of splenectomy	16
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study	16
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas	15
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso‐occlusive episodes during the randomized, open‐label HELPS study	15
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?	15
Fetal and neonatal alloimmune thrombocytopenia: No evidence of systemic inflammation as a modulator of disease severity. Could placental inflammation be key?	15
Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder	15
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia	15
Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect	15
Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study	15
Survival prediction optimization of acute myeloid leukaemia based on T‐cell function‐related genes and plasma proteins	15
Effect of peptide‐binding motif on survival of HLA‐haploidentical transplantation with post‐transplant cyclophosphamide	15
Prognostic impact of FLT3‐ITD mutation on NPM1+ acute myeloid leukaemia patients and related molecular mechanisms	15
Biochemical screening of glucose‐6‐phosphate dehydrogenase deficiency in borderline cases: Complementary inputs of standardization enzymes and comparison with genetic status	15
A rare homozygous variant in TERT gene causing variable bone marrow failure, fragility fractures, rib anomalies and extremely short telomere lengths with high serum IgE	15
How to discover the exceptional venetoclax responders in AML/MDS?	15
Spurious thrombocytosis, red cell count and mean cell volume in a patient with thermal burns	15
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis	15
Single‐cell profiling of ineffective erythropoiesis in a mouse model of β‐thalassaemia intermedia	15
Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3‐PBX1 positive acute lymphoblastic leukaemia	15
Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia	15
The distribution and accumulation of the shortest telomeres in telomere biology disorders	14
Idecabtagene vicleucel: questions regarding the appropriate role and cost	14
High on‐treatment platelet reactivity—an OPTIMAl solution, or a better solution?	14
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial	14
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma	14
Dimethyl fumarate ameliorates graft‐versus‐host disease by inhibiting T‐cell metabolism and immune responses through a reactive oxygen species‐dependent mechanism	14
Predicting therapy‐related myeloid neoplasms after CAR‐T with the Clonal Haematopoiesis Risk Score (CHRS)	14
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion‐dependent thalassemia patient following treatment with luspatercept: A case report	14
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target	14
Cryoglobulin crystals deposited in a peripheral blood film and phagocytosed by neutrophils	14
Transfusion of red cells from donors with hereditary haemochromatosis improve haemoglobin increments in patients	14
Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes	14
	14
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia	14
Multiple myeloma with acicular crystalline inclusion bodies	14
Proteomic analysis of neutrophils from patients with COVID‐19	14
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study	14
Gaps in the diagnosis and management of iron overload in sickle cell disease: a ‘real‐world’ report from the GRNDaD registry	14
Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan	14
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study	14
Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission	14
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	14
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation	14
External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registr	14
Long‐term real‐world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all‐trans retinoic acid without chemotherapy—a retrospective, single‐centre study	14
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	13
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response	13
Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and pa	13
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa	13
Issue Information	13
Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?	13
The Russian invasion of Ukraine: Implications for haematologists	13
Drug‐induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data	13
Anti‐severe acute respiratory syndrome coronavirus‐2 adenoviral‐vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers	13
	13
Expression of Concern: Effect of insulin‐like growth factor 1 on PHA‐stimulated cord blood mononuclear cell telomerase activity	13
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia	13
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights	13
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment	13
Issue Information	13
Inflammatory profile of lower risk myelodysplastic syndromes	13
Resolving sticky relationships between platelets and lymphocytes in COVID‐19: A role for checkpoint inhibitors?	13
Molecular monitoring of myelodysplastic neoplasm: Don't just watch this space, consider the patient's ancestry	13
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency	13
Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy	13
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation fr	13
PF4 promotes CXCR3+ Tfh1 cell differentiation through STAT1 in mouse immune thrombocytopenia	13
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis	13
Chronic refractory immune thrombocytopenia in adolescents and young adults	13
Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy	13
Erratum	13
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm	13
Frequent health care utilisation and avascular necrosis are associated with cannabis use in adults with sickle cell disease	13
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome	13
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)	13
The continuing global challenges of treating patients with beta‐thalassemia	12
Benefit of repeatedCOVID‐19 vaccination for patients with B‐cell malignancies	12
Influenza A (H1N1) virus induced long‐term remission in a refractory acute myeloid leukaemia	12
Acquired uniparental isodisomies involving chromosome 12 in paediatric B‐cell precursor acute lymphoblastic leukaemia: Associations with chromosome 21 gains and SH2B3 mutations	12
Major haemorrhage: putting evidence into practice	12
Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow	12
Platelet count decline and high neutrophil count within the first day of admission for painful sickle cell vaso‐occlusive episodes predict severe complications	12
Everyone is entitled to his or her own opinion but not to their own facts*	12
Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia	12
Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India	12
Vacuolated lymphocytes as initial presentation of angioimmunoblastic T‐cell lymphoma	12
FISH‐ing for answers: Can genomic arrays add to our understanding of disease biology in low‐risk chronic lymphocytic leukaemia?	12
From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics	12
Infection with Neoehrlichia mikurensis promotes the development of malignant B‐cell lymphomas	12